<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>BLEPHAMIDE - sulfacetamide sodium and prednisolone acetate suspension/ drops </strong><br>Physicians Total Care, Inc.<br></p></div>
<h1>BLEPHAMIDE<span class="Sup">®</span><br>(sulfacetamide sodium – prednisolone acetate ophthalmic suspension, USP) 10%/0.2%
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s1"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION
</h1>
<p class="First">BLEPHAMIDE<span class="Sup">®</span> ophthalmic suspension is a topical anti-inflammatory/anti-infective combination product for ophthalmic use.
</p>
<p><span class="Bold">Structural Formulas:</span></p>
<div class="Figure">
<a name="f1"></a><img alt="Structural Formulas
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=69465827-dd70-483e-84c7-ced49af5d189&amp;name=structuralformula.jpg">
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s2"></a><a name="section-1.1"></a><p></p>
<h2>Chemical Names:
</h2>
<p class="First">Sulfacetamide sodium:  N-sulfanilylacetamide monosodium salt monohydrate.
</p>
<p>Prednisolone acetate:  11ß, 17, 21-trihydroxypregna-1, 4-diene-3, 20-dione 21-acetate.
</p>
<p><span class="Bold">Contains:</span></p>
<p><span class="Bold">Actives:</span>  sulfacetamide sodium 10%, prednisolone acetate (microfine suspension) 0.2%.
</p>
<p><span class="Bold">Preservative:</span>  benzalkonium chloride (0.004%).  <span class="Bold">Inactives:</span> edetate disodium; polysorbate 80; polyvinyl alcohol 1.4%; potassium phosphate, monobasic; purified water; sodium phosphate, dibasic; sodium thiosulfate; hydrochloric acid and/or sodium hydroxide to adjust the pH (6.6 to 7.2).
</p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s3"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY
</h1>
<p class="First">Corticosteroids suppress the inflammatory response to a variety of agents and they probably delay or slow healing.  Since corticosteroids may inhibit the body's defense mechanism against <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, a concomitant antibacterial drug may be used when this inhibition is considered to be clinically significant in a particular case.
</p>
<p>When a decision to administer both a corticosteroid and an antibacterial is made, the administration of such drugs in combination has the advantage of greater patient compliance and convenience, with the added assurance that the appropriate dosage of both drugs is administered. When both types of drugs are in the same formulation, compatibility of ingredients is assured and the correct volume of drug is delivered and retained.  The relative potency of corticosteroids depends on the molecular structure, concentration and release from the vehicle.
</p>
<div class="Section" data-sectionCode="49489-8">
<a name="s4"></a><a name="section-2.1"></a><p></p>
<p class="First"><span class="Bold">Microbiology</span>:  Sulfacetamide sodium exerts a bacteriostatic effect against susceptible bacteria by restricting the synthesis of folic acid required for growth through competition with p-aminobenzoic acid.
</p>
<p>Some <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of these bacteria may be resistant to sulfacetamide or resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> may emerge <span class="Italics">in vivo</span>.
</p>
<p>The anti-infective component in these products is included to provide action against specific organisms susceptible to it.  Sulfacetamide sodium is active <span class="Italics">in vitro</span> against susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms:  <span class="Italics">Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus (viridans</span> group<span class="Italics">), Haemophilus influenzae, Klebsiella</span> species, and <span class="Italics">Enterobacter</span> species.  This product does not provide adequate coverage against: <span class="Italics">Neisseria</span> species, <span class="Italics">Pseudomonas</span> species, and <span class="Italics">Serratia marcescens</span> (see <span class="Bold"><a href="#s5">INDICATIONS AND USAGE</a></span>).
</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s5"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE
</h1>
<p class="First">A steroid/anti-infective combination is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or a risk of bacterial ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> exists.
</p>
<p>Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain diminution in <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> and <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>.  They are also indicated in chronic <span class="product-label-link" type="condition" conceptid="434926" conceptname="Iridocyclitis">anterior uveitis</span> and corneal injury from chemical, radiation or <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">thermal burns</span> or penetration of foreign bodies.
</p>
<p>The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye.
</p>
<p>The particular antibacterial drug in this product is active against the following common bacterial eye pathogens:  <span class="Italics">Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus  (viridans</span> group<span class="Italics">), Haemophilus influenzae, Klebsiella</span> species<span class="Italics">,</span> and <span class="Italics">Enterobacter</span> species.  This product does not provide adequate coverage against: <span class="Italics">Neisseria</span> species<span class="Italics">, Pseudomonas</span> species, and<span class="Italics"> Serratia marcescens</span>.
</p>
<p>A significant percentage of staphylococcal isolates are completely resistant to sulfa drugs.
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s6"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS
</h1>
<p class="First">BLEPHAMIDE<span class="Sup">®</span> ophthalmic suspension is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial <span class="product-label-link" type="condition" conceptid="373404" conceptname="Ophthalmic herpes simplex">herpes simplex keratitis</span> (<span class="product-label-link" type="condition" conceptid="373404" conceptname="Ophthalmic herpes simplex">dendritic keratitis</span>), <span class="product-label-link" type="condition" conceptid="140633" conceptname="Vaccinia">vaccinia</span>, and <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span>, and also in <span class="product-label-link" type="condition" conceptid="4009326" conceptname="Mycobacterial infection">mycobacterial infection</span> of the eye and fungal diseases of ocular structures.
</p>
<p>This product is also contraindicated in individuals with known or suspected <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of the ingredients of this preparation, to other sulfonamides and to other corticosteroids.  See <span class="Bold"><a href="#s7">WARNINGS</a></span>.  (<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to the antimicrobial component occurs at a higher rate than for other components.)
</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="s7"></a><a name="section-5"></a><p></p>
<h1>WARNINGS
</h1>
<p class="First">NOT FOR INJECTION INTO THE EYE.
</p>
<p>Prolonged use of corticosteroids may result in <span class="product-label-link" type="condition" conceptid="381290" conceptname="Ocular hypertension">ocular hypertension</span>/<span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> with damage to the optic nerve, defects in visual acuity and fields of vision, and in <span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">posterior subcapsular cataract</span> formation.
</p>
<p>Acute <span class="product-label-link" type="condition" conceptid="434926" conceptname="Iridocyclitis">anterior uveitis</span> may occur in susceptible individuals, primarily Blacks.
</p>
<p>Prolonged use of BLEPHAMIDE<span class="Sup">®</span> ophthalmic suspension may suppress the host response and thus increase the hazard of secondary ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.  In those diseases causing thinning of the cornea or sclera, perforation has been known to occur with the use of topical corticosteroids.  In acute purulent conditions of the eye, corticosteroids may mask <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or enhance existing <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.
</p>
<p>If the product is used for 10 days or longer, intraocular pressure should be routinely monitored even though it may be difficult in children and uncooperative patients.  Corticosteroids should be used with caution in the presence of <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>.  Intraocular pressure should be checked frequently.
</p>
<p>A significant percentage of staphylococcal isolates are completely resistant to sulfonamides.
</p>
<p>The use of steroids after <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> surgery may delay healing and increase the incidence of filtering blebs.
</p>
<p>The use of ocular corticosteroids may prolong the course and may exacerbate the severity of many <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> of the eye (including herpes simplex).  Employment of  corticosteroid medication in the treatment of herpes simplex requires great caution.
</p>
<p>Topical steroids are not effective in mustard gas <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span> and Sjögren's <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratoconjunctivitis</span>.
</p>
<p>Fatalities have occurred, although rarely, due to severe reactions to sulfonamides including <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, fulminant <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span> and other <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood dyscrasias</span>.  Sensitization may recur when a sulfonamide is readministered, irrespective of the route of administration.
</p>
<p>If signs of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> or other serious reactions occur, discontinue use of this preparation.  Cross-sensitivity among corticosteroids has been demonstrated   (see <span class="Bold"><a href="#s17">ADVERSE REACTIONS</a></span>).
</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="s8"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="s9"></a><a name="section-6.1"></a><p></p>
<h2>General:
</h2>
<p class="First">The initial prescription and renewal of the medication order beyond 20 milliliters of the suspension should be made by a physician only after examination of the patient with the aid of magnification, such as slit lamp biomicroscopy and, where appropriate, fluorescein staining.  If signs and symptoms fail to improve after two days, the patient should be re-evaluated.
</p>
<p>The possibility of <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> of the cornea should be considered after prolonged corticosteroid dosing.  Use with caution in patients with severe <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eye</span>.  Fungal cultures should be taken when appropriate.
</p>
<p>The p-aminobenzoic acid present in purulent exudates competes with sulfonamides and can reduce their effectiveness.
</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s10"></a><a name="section-6.2"></a><p></p>
<h2>Information for Patients:
</h2>
<p class="First">If <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> persists longer than 48 hours or becomes aggravated, the patient should be advised to discontinue use of the medication and consult a physician (see <span class="Bold"><a href="#s7">WARNINGS</a></span>).
</p>
<p>Contact lenses should not be worn during the use of this product.
</p>
<p>This product is sterile when packaged.  To prevent contamination, care should be taken to avoid touching the applicator tip to eyelids or to any other surface.  The use of this bottle by more than one person may spread <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.  Keep bottle tightly closed when not in use.  Protect from light.  Sulfonamide solutions darken on prolonged standing and exposure to heat and light.  Do not use if solution has darkened.  Yellowing does not affect activity.  Keep out of the reach of children.
</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="s11"></a><a name="section-6.3"></a><p></p>
<h2>Laboratory Tests:
</h2>
<p class="First">Eyelid cultures and tests to determine the susceptibility of organisms to sulfacetamide may be indicated if signs and symptoms persist or recur in spite of the recommended course of treatment with BLEPHAMIDE<span class="Sup">®</span> ophthalmic suspension.
</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s12"></a><a name="section-6.4"></a><p></p>
<h2>Drug Interactions:
</h2>
<p class="First">BLEPHAMIDE<span class="Sup">®</span> ophthalmic suspension is incompatible with silver preparations.  Local anesthetics related to p-aminobenzoic acid may antagonize the action of the sulfonamides.
</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="s13"></a><a name="section-6.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility:
</h2>
<p class="First">Prednisolone has been reported to be noncarcinogenic.  Long-term animal studies for carcinogenic potential have not been performed with sulfacetamide.
</p>
<p>One author detected chromosomal nondisjunction in the yeast  <span class="Italics">Saccharomyces cerevisiae</span> following application of sulfacetamide sodium.  The significance of this finding to topical ophthalmic use of sulfacetamide sodium in the human is unknown.
</p>
<p>Mutagenic studies with prednisolone have been negative.  Studies on reproduction and fertility have not been performed with sulfacetamide.  A long-term chronic toxicity study in dogs showed that high oral doses of prednisolone prevented estrus.  A decrease in fertility was seen in male and female rats that were mated following oral dosing with another glucocorticosteroid.
</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="s14"></a><a name="section-6.6"></a><p></p>
<h2>Pregnancy:
</h2>
<p class="First">Teratogenic Effects:  Pregnancy Category C.  Animal reproduction studies have not been conducted with sulfacetamide sodium.  Prednisolone has been shown to be teratogenic in rabbits, hamsters, and mice.  In mice, prednisolone has been shown to be teratogenic when given in doses 1 to 10 times the human ocular dose.  Dexamethasone, hydrocortisone and prednisolone were ocularly applied to both eyes of pregnant mice five times per day on days 10 through 13 of gestation.  A significant increase in the incidence of <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span> was observed in the fetuses of the treated mice.  There are no adequate well-controlled studies in pregnant women dosed with corticosteroids.
</p>
<p><span class="product-label-link" type="condition" conceptid="4326231" conceptname="Kernicterus">Kernicterus</span> may be precipitated in infants by sulfonamides being given systemically during the third trimester of pregnancy.  It is not known whether sulfacetamide sodium can cause fetal harm when administered to a pregnant woman or whether it can affect reproductive capacity.
</p>
<p>BLEPHAMIDE<span class="Sup">®</span> ophthalmic suspension should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s15"></a><a name="section-6.7"></a><p></p>
<h2>Nursing Mothers:
</h2>
<p class="First">It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk.  Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects.  Systemically administered sulfonamides are capable of producing <span class="product-label-link" type="condition" conceptid="4326231" conceptname="Kernicterus">kernicterus</span> in infants of lactating women.  Because of the potential for serious adverse reactions in nursing infants from sulfacetamide sodium and prednisolone acetate ophthalmic suspensions, a decision should be made whether to discontinue nursing or to discontinue the medication.
</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s16"></a><a name="section-6.8"></a><p></p>
<h2>Pediatric Use:
</h2>
<p class="First">Safety and effectiveness in pediatric patients below the age of six have not been established.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s17"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS
</h1>
<p class="First">Adverse reactions have occurred with corticosteroid/antibacterial combination drugs which can be attributed to the corticosteroid component, the antibacterial component, or the combination.  Exact incidence figures are not available since no denominator of treated patients is available.
</p>
<p>Reactions occurring most often from the presence of the antibacterial ingredient are allergic sensitizations.  Fatalities have occurred, although rarely, due to severe reactions to sulfonamides including <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, fulminant <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, and other <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood dyscrasias</span> (See <span class="Bold"><a href="#s7">WARNINGS</a></span>).
</p>
<p>Sulfacetamide sodium may cause local irritation.
</p>
<p>The reactions due to the corticosteroid component in decreasing order of frequency are: elevation of intraocular pressure (IOP) with possible development of <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> and infrequent optic <span class="product-label-link" type="condition" conceptid="381732" conceptname="Nerve injury">nerve damage</span>, <span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">posterior subcapsular cataract</span> formation, and delayed <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing.
</p>
<p>Although systemic effects are extremely uncommon, there have been rare occurrences of systemic <span class="product-label-link" type="condition" conceptid="195212" conceptname="Hypercortisolism">hypercorticoidism</span> after use of topical corticosteroids.
</p>
<p>Corticosteroid-containing preparations can also cause acute <span class="product-label-link" type="condition" conceptid="434926" conceptname="Iridocyclitis">anterior uveitis</span> or perforation of the globe.  <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">Mydriasis</span>, loss of accommodation and <span class="product-label-link" type="condition" conceptid="373194" conceptname="Paralytic ptosis">ptosis</span> have occasionally been reported following local use of corticosteroids.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s18"></a><a name="section-7.1"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="442777" conceptname="Generalized infection during labor">Secondary infection</span>:</span>  The development of <span class="product-label-link" type="condition" conceptid="442777" conceptname="Generalized infection during labor">secondary infection</span> has occurred after use of combinations containing corticosteroids and antibacterials.  Fungal and <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> of the cornea are particularly prone to develop coincidentally with long-term applications of corticosteroid.  The possibility of fungal invasion must be considered in any persistent <span class="product-label-link" type="condition" conceptid="373202" conceptname="Corneal ulcer">corneal ulceration</span> where corticosteroid treatment has been used.
</p>
<p>Secondary bacterial ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> following suppression of host responses also occurs.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s19"></a><a name="section-8"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION
</h1>
<p class="First">SHAKE WELL BEFORE USING.  Two drops should be instilled into the conjunctival sac every four hours during the day and at bedtime.
</p>
<p>Not more than 20 milliliters should be prescribed initially, and the prescription should not be refilled without further evaluation as outlined in <span class="Bold"><a href="#s8">PRECAUTIONS</a></span> above.
</p>
<p>BLEPHAMIDE<span class="Sup">®</span> dosage may be reduced, but care should be taken not to discontinue therapy prematurely.  In chronic conditions, withdrawal of treatment should be carried out by gradually decreasing the frequency of application.
</p>
<p>If signs and symptoms fail to improve after two days, the patient should be re-evaluated (see <span class="Bold"><a href="#s8">PRECAUTIONS</a></span>).
</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s20"></a><a name="section-9"></a><p></p>
<h1>HOW SUPPLIED
</h1>
<p class="First">BLEPHAMIDE<span class="Sup">®</span> (sulfacetamide sodium–prednisolone acetate ophthalmic suspension, USP) is supplied sterile in opaque white LDPE plastic bottles and white dropper tips with white high impact polystyrene (HIPS) caps as follows:
</p>
<p>5 mL in 10 mL bottle — NDC 54868-0634-1<br>  10 mL in 15 mL bottle</p>
<p><span class="Bold">Note:</span>  Protect from freezing.  <span class="Bold">Shake well before using.</span></p>
<div class="Section" data-sectionCode="44425-7">
<a name="s21"></a><a name="section-9.1"></a><p></p>
<p class="First"><span class="Bold">Storage:</span>  Store at 8°-24°C (46°-75°F) in an upright position.
</p>
<p>PROTECT FROM LIGHT.
</p>
<p>Sulfonamide solutions darken on prolonged standing and exposure to heat and light.  Do not use if solution has darkened.  Yellowing does not affect activity.
</p>
<p>KEEP OUT OF REACH OF CHILDREN.
</p>
<p><span class="Bold">Rx  only</span></p>
<p>Revised June 2004
</p>
<p>© 2004 Allergan, Inc.<br>Irvine, CA 92612, U.S.A.<br>® marks owned by Allergan, Inc.<br>6580X<br>71735US10P
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2"></a><p></p>
<p class="First">Distributed by:<br>Physicians Total Care, Inc.<br>Tulsa, OK        74146<br></p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="j1"></a><a name="section-10"></a><p></p>
<h1>Carton PDP
</h1>
<p class="First"><span class="Bold">ALLERGAN</span></p>
<p><br></p>
<p><span class="Bold">Rx Only</span></p>
<p><span class="Bold">BLEPHAMIDE®</span></p>
<p>(sulfacetamide
</p>
<p>sodium -
</p>
<p>prednisolone
</p>
<p>acetate
</p>
<p>ophthalmic
</p>
<p>suspension, USP)
</p>
<p>10%/0.2%
</p>
<p>sterile
</p>
<p><span class="Bold">10 mL</span></p>
<div class="Figure"><img alt="Carton PDP" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=69465827-dd70-483e-84c7-ced49af5d189&amp;name=carton.jpg"></div>
<br><div class="Figure"><img alt="package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=69465827-dd70-483e-84c7-ced49af5d189&amp;name=0634.jpg"></div>
<br>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>BLEPHAMIDE 		
					</strong><br><span class="contentTableReg">sulfacetamide sodium and prednisolone acetate suspension/ drops</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-0634(NDC:11980-022)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>sulfacetamide sodium</strong> (sulfacetamide) </td>
<td class="formItem">sulfacetamide sodium</td>
<td class="formItem">100 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>prednisolone acetate</strong> (prednisolone) </td>
<td class="formItem">prednisolone acetate</td>
<td class="formItem">2 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>benzalkonium chloride</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>edetate disodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>polysorbate 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>polyvinyl alcohol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>potassium phosphate, monobasic</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium phosphate, dibasic</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium thiosulfate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>hydrochloric acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-0634-1</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">5 mL in 1 BOTTLE, DROPPER</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA012813</td>
<td class="formItem">10/01/1961</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel(54868-0634)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 11/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>242d8816-a52b-4df5-ac07-f3ebf13004b8</div>
<div>Set id: 69465827-dd70-483e-84c7-ced49af5d189</div>
<div>Version: 1</div>
<div>Effective Time: 20131115</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
